As a pioneer at the forefront of brain disorders for more than 60 years, Lundbeck is committed to developing and providing innovative therapies that help improve the quality of life of patients. This is important work because the burden of neurological and psychiatric disorders remains substantial. When they assess a medical condition, they see the person behind the disease and how it affects the lives of patients, their families, their caregivers and their communities.
Lundbeck is a global pharmaceutical company highly committed to improving the quality of life of people living with psychiatric and neurological disorders. For this purpose, Lundbeck is engaged in the research, development, production, marketing and sale of pharmaceuticals across the world. The company’s products are targeted at disease areas such as depression, schizophrenia, Parkinson’s disease and Alzheimer’s disease.
Lundbeck employs approximately 5,000 people worldwide. They have employees in 55 countries, and our products are registered in more than 100 countries. They have production facilities in China, Denmark, France and Italy and research centers in Denmark and China. Lundbeck generated revenue of approximately DKK 14.6 billion in 2015.